Metabolism Disorder TRIZ Cases

Integrated porous channels raise surface area to volume, improving oxygen and nutrient transport to support viable, productive cell matrices.

A hydro-ethanolic cinnamon bark extract concentrates polyphenols to lower glycemic index in foods without the flavor and form limits of existing agents.

Amino acids, chelators, and surfactants stabilize anti-α4β7 antibody liquids, limiting degradation and aggregation for subcutaneous dosing.

CD73-positive fibroblasts promote tolerogenic immune responses that protect transplanted islets, improve engraftment, and stabilize glucose control.

An acidic pH and propylene glycol formulation boosts theta-defensin bioavailability while lowering viscosity and injection site reactions.

Liver-targeted AAV8 delivery of codon-optimized hPAH enables sustained enzyme expression to lower plasma phenylalanine in PKU.

Semaglutide use in type 2 diabetes addresses glycaemic control limits while reducing major adverse cardiovascular event risk.

Arginine-degrading enzymes deplete arginine to reduce body and liver fat, improve insulin sensitivity, and ease reliance on unsustainable diets.

Co-crystallizing methylxanthines with stilbenoids masks bitter taste and improves bioavailability for nutraceutical and pharmaceutical use.

rAAV delivery of codon-optimized BCKDHA and BCKDHB restores BCKD activity in liver or muscle, avoiding transplant risks in MSUD.

Migalastat stabilizes mutant α-Gal A and improves lysosomal trafficking, offering a Fabry disease treatment beyond enzyme replacement limits.

Short CD40-binding peptides block CD40-CD154 signaling to reduce autoimmune inflammation and type 2 diabetes with fewer side effects.

High-affinity antibodies bind the PRLR extracellular domain to block receptor activation with selective therapeutic action in PRLR-related diseases.

Non-absorbable indane NHE inhibitors block GI sodium and water absorption to ease fluid retention and GI pain with fewer renal side effects.

Structural modification of selective ETBR agonist polypeptides extends half-life and exposure while reducing dosing frequency and side effects in stroke recovery.

Plasminogen reduces abnormal fat deposition and body weight, offering a safer obesity treatment than existing weight-loss drugs.

Unmodified codon-optimized MUT mRNA in a lipid formulation sustains liver protein expression and lowers methylmalonic acid in MMA.

3D organoid culture and FACS-isolated endocrine progenitors enable long-term expansion of glucose-responsive insulin-secreting β-cells.

A THCV composition with CBG or CBND targets appetite suppression and weight loss while aiming to reduce side effects seen with obesity drugs.

Controlling migalastat hydrochloride to d(0.9) below 200 µm improves capsule flowability, content uniformity, dissolution, and stability.

Sequential stem cell differentiation into pancreatic endocrine precursors improves scalable cell production for blood glucose lowering.

Specific PYY analogue modifications improve pH 6-7 solubility, stability, and half-life while preserving selective NPY2 receptor activity.

AAV-mediated FGF21 gene delivery enables long-lasting native secretion in liver, adipose tissue, or muscle while reducing immunogenicity.

Using beta-lactoglobulin at high protein purity raises both insulin and glucagon to support metabolic disorder and muscle atrophy treatment.

A 12-day high-dose teplizumab regimen preserves beta cell function and improves glycemic control while guiding retreatment by T-cell monitoring.

Targeted epitope mutations in alpha-galactosidase A reduce immune responses and neutralizing antibodies while preserving Fabry ERT activity.

Oral low-dose DDA reduces liver fibrosis and NASH while supporting glucose control, mitochondrial biogenesis, and cytoprotection.

Fermenting Panax ginseng with Lactobacillus plantarum improves absorption while suppressing hypoxia and cholesterol buildup in kidney and vascular disease.

Formula I GIPR antagonists use substituent tuning to improve selectivity, efficacy, and safety in obesity and T2DM treatment.

Alistipes bacteria and their membrane vesicles suppress adipocyte differentiation and lipid accumulation, offering anti-obesity action with fewer side effects.

A multi-component formulation combines anti-inflammatory, astringent, and cooling agents to speed diabetic chronic wound healing.

An oral tirzepatide formulation uses oils, bile salts, and sodium bicarbonate to avoid injections while improving glycemic control and weight loss.

Co-induced vesicle release packages mitochondria inside microvesicles, improving preservation, storage, and delivery into damaged cells.

Modified GPR75 inhibitor peptides reduce food intake and body weight without bariatric surgery, improving obesity treatment access.

Hexahydropentalene derivatives tune LRH-1 binding-site interactions to improve gene regulation consistency and therapeutic specificity.

Early administration of EGCG, sulforaphane, olive compounds, or insulin mimotope peptides aims to induce immune tolerance and prevent type 1 diabetes.

A mixed hydrogenated curcuminoid composition addresses metabolic syndrome by lowering lipids and glucose while avoiding conventional drug side effects.

Peptide receptor agonists are tuned for longer half-life, lower fibrillation risk, and weekly dosing while preserving metabolic efficacy.

An osteogenic HKUOT-S2 protein promotes bone repair and preserves osteoblast-osteoclast balance without graft morbidity or drug-like side effects.

Avexitide blocks excess GLP-1 signaling after gastrointestinal surgery to improve intake, limit weight loss, and ease GI symptoms.

CRISPR-Cas9 disruption of Nrip1 in adipose progenitor cells creates thermogenic adipocytes that improve glucose tolerance while limiting off-target effects.

Methylated phloretin analogs inhibit SGLT2 with better bioavailability and lower gastrointestinal side effects for metabolic health use.

Site-specific peptide modifications improve MC4R selectivity and potency, helping treat obesity and cognitive loss with fewer side effects.

Combining FASN inhibitors with THRβ agonists improves liver fat reduction while better addressing inflammation and fibrosis in MASLD.

Covalently linked α-galactosidase multimers improve lysosomal and serum stability, extending half-life and reducing immunogenicity in Fabry therapy.

Specific dosing of hypoimmunogenic islet cells with reduced MHC and higher CD47 improves engraftment, insulin production, and glucose stability.

Exogenous 3-hydroxybutyrate precursors help delay overtraining, reduce muscle damage, and stabilize hormonal levels during heavy training.

Annexin A5 helps repair refractory wounds by reducing inflammation and improving neovascularization and collagen deposition.

Two sequential RP-HPLC steps at constant pH plus salt exchange purify liraglutide while avoiding precipitation and reducing process complexity.

Dual GIP/GLP-1 agonist compounds use sequence and fatty-acid modifications to extend action, support oral dosing, and improve glucose and weight control.